Literature DB >> 9042216

Reversible inhibition of IL-8 receptor B mRNA expression and proliferation in non-small cell lung cancer by antisense oligonucleotides.

G Olbina1, D Cieslak, S Ruzdijic, C Esler, Z An, X Wang, R Hoffman, W Seifert, Z Pietrzkowski.   

Abstract

We examined the importance of IL-8 receptor B mRNA expression in the growth of non-small cell lung cancer (NSCLC). Using antisense oligonucleotide ICN 197, we were able to inhibit IL-8 R B mRNA expression in vitro. The sequence specific effect of antisense oligonucleotide and down-regulation of IL-8 R B mRNA was shown by Reverse Transcription Polymerase Chain Reaction (RT-PCR) and Southern blot analysis. The proliferation of treated cells was measured by 3H thymidine incorporation. We found that treatment of NSCLC cells caused reversible growth inhibition and reversible down regulation of IL-8 R B mRNA. Furthermore, we observed that the treatment of nude mice with oligonucleotide ICN 197 inhibited the growth of tumors developed from NSCLC cells injected subcutaneously. Our data in vitro suggest that IL-8 receptor B mRNA expression is required to maintain the proliferative rate of NSCLC. Based on the data in vivo. oligonucleotide ICN 197 may be considered for the development of novel therapeutic treatment for lung cancer.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 9042216

Source DB:  PubMed          Journal:  Anticancer Res        ISSN: 0250-7005            Impact factor:   2.480


  6 in total

1.  Differential regulation of CXC ligand 1 transcription in melanoma cell lines by poly(ADP-ribose) polymerase-1.

Authors:  K I Amiri; H C Ha; M E Smulson; A Richmond
Journal:  Oncogene       Date:  2006-06-26       Impact factor: 9.867

Review 2.  The CC and CXC chemokines: major regulators of tumor progression and the tumor microenvironment.

Authors:  Andreas Bikfalvi; Clotilde Billottet
Journal:  Am J Physiol Cell Physiol       Date:  2020-01-08       Impact factor: 4.249

Review 3.  Orthotopic metastatic mouse models for anticancer drug discovery and evaluation: a bridge to the clinic.

Authors:  R M Hoffman
Journal:  Invest New Drugs       Date:  1999       Impact factor: 3.850

Review 4.  The role of CXC chemokines and their receptors in the progression and treatment of tumors.

Authors:  Qingchao Zhu; Xiaodong Han; Jiayuan Peng; Huanlong Qin; Yu Wang
Journal:  J Mol Histol       Date:  2012-06-30       Impact factor: 2.611

Review 5.  Fine tuning the transcriptional regulation of the CXCL1 chemokine.

Authors:  Katayoun Izadshenas Amiri; Ann Richmond
Journal:  Prog Nucleic Acid Res Mol Biol       Date:  2003

6.  Revisiting immunosurveillance and immunostimulation: Implications for cancer immunotherapy.

Authors:  Christine V Ichim
Journal:  J Transl Med       Date:  2005-02-08       Impact factor: 5.531

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.